STAMFORD, Conn., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe...
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary...
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary...
Four cancer types now included in PeptiCRAd-1 with Pembrolizumab trial: sarcoma, melanoma, triple negative breast cancer and non-small cell lung...
STONY BROOK, NY / ACCESSWIRE / November 28, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...
SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of...
- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as...
- Topline results from FemaSeed® pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 -...
Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a...
Cohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or...
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end...
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the...
Key apps from the iCAD Breast Health Suite are now integrated with GE HealthCare’s new MyBreastAI Suite*AI applications streamline workflow...
NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company...
Upgrade of Gamma Knife® 4C with NEW Elekta ICON for most precise and accurate treatment of Intracranial cancers and other...
Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant...
Designation is for 2nd or 3rd line treatment of patients with disease progression following treatment with endocrine therapy and a...
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage...
AGOURA HILLS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”),...